Page last updated: 2024-11-06

idazoxan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Idazoxan is a non-selective alpha2-adrenergic receptor antagonist. It is a synthetic compound structurally related to yohimbine and is used in research to study the role of alpha2-adrenergic receptors in various physiological processes. Idaxozan has a high affinity for alpha2A and alpha2B receptors, but also interacts with alpha2C receptors to a lesser extent. It can be administered orally or intravenously. The effects of idazoxan include an increase in blood pressure, heart rate, and sympathetic nervous system activity. It is also known to have anxiolytic effects, and has been studied as a potential treatment for anxiety disorders. Idazoxan has been shown to be effective in reducing anxiety in animal models. Idazoxan is an important tool in the study of alpha2-adrenergic receptors. It is a potent antagonist that can be used to selectively block the effects of these receptors. This allows researchers to study the role of alpha2-adrenergic receptors in a variety of physiological processes. For example, idazoxan has been used to study the role of alpha2-adrenergic receptors in the regulation of blood pressure, heart rate, and anxiety. Idazoxan is also being studied as a potential treatment for a number of conditions, including anxiety disorders, depression, and Parkinson's disease. Idazoxan is a valuable research tool that has contributed significantly to our understanding of alpha2-adrenergic receptors.'

Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID54459
CHEMBL ID10316
CHEBI ID5862
SCHEMBL ID114731
MeSH IDM0028778

Synonyms (76)

Synonym
AB00489883-09
BRD-A18696154-003-03-6
PRESTWICK2_000926
idazoxane [french]
1h-imidazole, 4,5-dihydro-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-
(+-)-2-(1,4-benzodioxan-2-yl)-2-imidazoline
idazoxano [spanish]
2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1h-imidazole
idazoxanum [latin]
PRESTWICK3_000926
BPBIO1_000916
BSPBIO_000832
idazoxano
idazoxanum
4,5-dihydro-2-(2,3-dihydro-1,4-benzodioxin-2-yl)-1h-imidazole
idazoxane
CHEBI:5862 ,
AB00514632
idazoxan
79944-58-4
LOPAC0_000652
NCGC00024794-04
SPBIO_003011
PRESTWICK1_000926
PRESTWICK0_000926
NCGC00024794-03
HMS2089E14
NCGC00015560-08
L000808
racemic idazoxan
dl-idazoxan
CHEMBL10316 ,
nsc-759867
FT-0655996
2-(2,3-dihydro-1,4-benzodioxin-3-yl)-4,5-dihydro-1h-imidazole
bdbm50019848
us8633208, idazoxan
NCGC00015560-06
A839791
idazoxan [inn:ban]
nsc 759867
unii-y310pa316b
y310pa316b ,
dtxsid6045161 ,
tox21_110173
cas-79944-58-4
dtxcid4025161
CCG-204739
NCGC00015560-10
NCGC00015560-09
NCGC00015560-04
NCGC00015560-05
AKOS015915004
2-imidazoline, 2-(1,4-benzodioxan-2-yl)-
1h-imidazole, 2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-
idazoxan [mi]
84720-37-6
(+/-)-idazoxan
(+/-)-2-(1,4-benzodioxan-2-yl)-2-imidazoline
idazoxan [inn]
SCHEMBL114731
NCGC00015560-12
tox21_110173_1
2-(1,4-benzodioxan-2-yl)imidazoline
tox21 110173
AB00489883_10
SBI-0050632.P002
idasoxan
DB12551
Q5987770
BRD-A18696154-003-14-3
SDCCGSBI-0050632.P003
NCGC00015560-17
2-(2,3-dihydrobenzo[b][1,4]dioxin-2-yl)-4,5-dihydro-1h-imidazole
tr-01-xrr
gtpl12575

Research Excerpts

Overview

Idazoxan is a labelled ligand that is frequently used to study alpha 2-adrenoceptors in the central nervous system. It is an alpha(2) adrenoceptor antagonist and alpha(1)/alpha(2), partial agonist which also blocks imidazoline receptors.

ExcerptReferenceRelevance
"Idazoxan is an alpha(2) adrenoceptor antagonist and alpha(1)/alpha(2) partial agonist which also blocks imidazoline receptors. "( Idazoxan effects upon contractile activity in the rat aorta are related to alpha adrenoceptors and L-type channels.
Nechifor, M; Serban, DN; Serban, IL, 2004
)
3.21
"Idazoxan is a new selective alpha 2-adrenoceptor antagonist which should prove a valuable investigative tool in neurochemical studies and which may be a useful clinical agent in the management of the affective disorders."( Effects of idazoxan on catecholamine systems in rat brain.
Burton, R; Dettmar, PW; Flockhart, IR; Haynes, MJ; Howlett, DR; Johnson, J; Lane, AC; Walter, DS, 1984
)
1.38
"(idazoxan acts as an indirect sympathomimetic drug through blockade of presynaptic alpha2-adrenoceptors)."( Glucose-induced sympathetic activity and energy expenditure during acute alpha2-adrenergic antagonism in obese subjects.
Barbe, P; Berlan, M; Galitzky, J; Lafontan, M; Montastruc, JL; Sénard, JM; Thalamas, C, 2000
)
0.93
"[3H]Idazoxan is a labelled ligand that is frequently used to study alpha 2-adrenoceptors in the central nervous system. "( Guanabenz, guanochlor, guanoxan and idazoxan bind with high affinity to non-adrenergic sites in pig kidney membranes.
Frelin, C; Lazdunski, M; Vigne, P, 1989
)
1.11

Effects

ExcerptReferenceRelevance
"Idazoxan, which has an imidazoline structure, proved to be a more active antagonist than yohimbine of rilmenidine centrally-mediated cardiovascular effects."( Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit.
Belcourt, A; Bousquet, P; Bricca, G; Dontenwill, M; Feldman, J; Tibiriça, E, 1990
)
1
"Idazoxan, which has an imidazoline structure, proved to be a more active antagonist than yohimbine of rilmenidine centrally-mediated cardiovascular effects."( Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit.
Belcourt, A; Bousquet, P; Bricca, G; Dontenwill, M; Feldman, J; Tibiriça, E, 1990
)
1

Actions

Idazoxan appears to produce effects resembling a "lightening of anesthesia" This may provide the impetus for further studies on the possibility of using alpha 2-adrenoceptor antagonists in the recovery from certain types of anesthetic agents.

ExcerptReferenceRelevance
"Idazoxan did not inhibit lordosis behavior in these males."( Idazoxan decreases estrogen-induced lordosis in female but not "hormone-independent" lordosis in male guinea pigs of an inbred strain.
Feder, HH; Goy, RW; McEwen, BS; Roy, M; Thornton, JE; Vincent, P, 1993
)
2.45
"IT idazoxan blocked the increase in both NE and ACh."( Cerebrospinal fluid norepinephrine and acetylcholine concentrations during acute pain.
D'Angelo, R; Detweiler, DJ; Eisenach, JC; Hood, DD; Tong, C, 1996
)
0.81
"Idazoxan was found to produce dose-dependent improvements in performance, particularly on tests of planning, sustained attention, verbal fluency and episodic memory."( The alpha(2) antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type.
Coull, JT; Hodges, JR; Sahakian, BJ, 1996
)
1.32
"Thus idazoxan appears to produce effects resembling a "lightening of anesthesia." This may provide the impetus for further studies on the possibility of using alpha 2-adrenoceptor antagonists in the recovery from certain types of anesthetic agents."( The anti-anesthetic action of idazoxan.
Majeed, AB, 1996
)
1.04
"Idazoxan failed to increase [Ca2+]i under any experimental condition tested."( Elevation of cytosolic calcium by imidazolines in mouse islets of Langerhans: implications for stimulus-response coupling of insulin release.
Dunne, MJ; Hashmi, MN; Kane, C; Shepherd, RM; Squires, PE, 1996
)
1.02
"Idazoxan alone did not increase duodenal motility but clonidine induced phase-III activity within the first 15 min after administration."( The effect of a new selective alpha 2-adrenoreceptor antagonist, idazoxan, and the agonist, clonidine, on fasting antroduodenal motility in healthy volunteers.
Gregersen, H; Kraglund, K; Rittig, S; Tøttrup, A, 1989
)
1.24

Treatment

Idazoxan did not alter the locomotor hyperactivity induced by acute morphine in control mice but potentiated it in morphine-withdrawn mice. Pretreatment with idazoxans (1 microgram/kg i.c.) significantly attenuated the hypotensive and sympathoinhibitory effects of rilmenidine.

ExcerptReferenceRelevance
"Idazoxan treatment facilitated recovery from spontaneous nicotine, but not amphetamine, withdrawal by attenuating reward deficits and increase the number of somatic signs."( The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats.
Markou, A; Semenova, S, 2010
)
1.35
"Idazoxan pretreatment prevented the sympathoinhibitory action of rilmenidine, whereas yohimbine pretreatment failed."( [The effect of rilmenidine on the sympathetic activity of the renal nerve in waking barodenervated rats].
Chernobel'skiĭ, MA; Maĭorov, DN; Medvedev, OS,
)
0.85
"Idazoxan pretreatment did not alter the locomotor hyperactivity induced by acute morphine in control mice but potentiated it in morphine-withdrawn mice."( The involvement of noradrenergic transmission in the morphine-induced locomotor hyperactivity in mice withdrawn from repeated morphine treatment.
Ahtee, L; Airio, J, 1999
)
1.02
"Idazoxan treatment only partially reversed the hypotension after alpha-MNA and had no effect on any of the baroreflex curves."( Comparison of renal sympathetic baroreflex effects of rilmenidine and alpha-methylnoradrenaline in the ventrolateral medulla of the rabbit.
Burke, SL; Head, GA, 2000
)
1.03
"Idazoxan pretreatment (1 mg/kg i.v.) attenuated the peak increase in hindquarters vascular resistance."( Adrenergic mechanisms underlying cardiac and vascular responses to cocaine in conscious rats.
Branch, CA; Knuepfer, MM, 1992
)
1
"idazoxan. Treatment with i.v."( Central sympathoinhibition and peripheral neuronal uptake blockade after desipramine in rabbits.
Angus, JA; Cox, HS; Dorward, PK; Eisenhofer, G; Esler, MD; Saigusa, T, 1991
)
1
"Idazoxan treatment of the males resulted in more hopping and earwiggling of the females before ejaculation."( The effects of idazoxan and 8-OH-DPAT on sexual behaviour and associated ultrasonic vocalizations in the rat.
Bloetjes, K; Mos, J; Olivier, B; Van Logten, J, 1991
)
1.36
"Treatment with idazoxan counteracted the observed Parkinsonian behaviour in 6-OHDA-lesioned rats and increased the spontaneous open-field activity in control rats."( The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?
Schmidt, WJ; Srinivasan, J, 2004
)
0.92
"Pretreatment with idazoxan (1 microgram/kg i.c.) significantly attenuated the hypotensive and sympathoinhibitory effects of rilmenidine, whereas i.c."( Sympathoinhibitory action of rilmenidine in conscious sinoaortically denervated rats.
Chernobelski, M; Mayorov, D; Medvedev, O, 1993
)
0.61
"Pretreatment with idazoxan (0.1 mg kg-1, i.v.)induced a nine fold shift to the right of the dose-response curve for amphetamine, while treatment with the depleting drug alpha-methyl-p-tyrosine (150mg kg-1 daily, i.p., for 14 days) abolished the inhibitory effect of this indirect adrenoceptor agonist on the OF-JOR.6."( Modulation by central postsynaptic alpha 2-adrenoceptors of the jaw-opening reflex induced by orofacial stimulation in rats.
Barturen, F; García-Sevilla, JA; García-Vallejo, P, 1994
)
0.61
"Pretreatment with idazoxan suppressed all the effects of mivazerol (n = 5)."( Catecholamine activation in the vasomotor center on emergence from anesthesia: the effects of alpha2 agonists.
Bruandet, N; Debeer, L; Quintin, L; Rentero, N, 1998
)
0.62
"treatment with idazoxan, an alpha2-adrenoceptor antagonist (300 and 1000 microg kg-1) and was not modified after i.v."( Characterization of mechanisms involved in presynaptic inhibition of sympathetic pressor effects induced by some 5-HT1 receptor antagonists.
Calama, E; Fernández, MM; Martín, ML; Morán, A; San Román, L,
)
0.47
"Pretreatment with idazoxan did not reduce the total cerebral blood flow and in such animals it increased from 53 +/- 1 to 75 +/- 4 g min-1 100 g-1 (P less than 0.01) after the administration of the lower dose of thyrotropin-releasing hormone and from 64 +/- 5 to 112 +/- 17 g min-1 100 g-1 (P less than 0.01) after the higher dose."( Effects of alpha 2-adrenoceptor blockade and thyrotropin-releasing hormone (TRH) on the cardiovascular system in the rabbit.
Koskinen, LO; Seligsohn, EE, 1991
)
0.6

Toxicity

ExcerptReferenceRelevance
" Taken together, these results demonstrate that MPClE is a novel, potent, orally active and safe analgesic drug that targets κ-opioid receptors."( A novel, potent, oral active and safe antinociceptive pyrazole targeting kappa opioid receptors.
Athayde, ML; Boligon, AA; Bonacorso, HG; Calixto, JB; Ferreira, J; Machado, P; Martins, MA; Oliveira, SM; Rosa, F; Rossato, MF; Rubin, MA; Silva, CR; Tonello, R; Trevisan, G; Walker, CI; Zanatta, N, 2013
)
0.39

Pharmacokinetics

ExcerptReferenceRelevance
" Half-life and mean residence time values ranged 105."( Pharmacokinetic profile of idazoxan in the beagle dog.
Menargues, A; Nomen, M; Obach, R; Pruñonosa, J; Vallès, J, 1989
)
0.57
" Values of clearance, volume of distribution and elimination half-life were 71."( A pharmacokinetic-pharmacodynamic linking model for the alpha 2-adrenergic antagonism of idazoxan on clonidine-induced mydriasis in the rat.
Jane, F; Menargues, A; Obach, R; Pruñonosa, J; Valles, J, 1995
)
0.51
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Bioavailability

Oral bioavailability in male rats at low oral doses of idazoxan (10 mg/kg) was about 1%, but increased with increasing dose to 23% at 100mg/kg. Bioavailability values obtained after the oral treatment ranged from 12 to 23%.

ExcerptReferenceRelevance
" The reversal of clonidine-induced mydriasis in the rat was used to assess bioavailability and indicated that 1b was a potent alpha 2-adrenoceptor antagonist in vivo."( Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptors.
Berger, J; Brown, CM; Clague, RU; Clark, RD; Kilpatrick, AT; MacKinnon, AC; Nelson, JT; Repke, DB; Spedding, M, 1991
)
0.28
" Bioavailability values ranged 60-88%."( Pharmacokinetic profile of idazoxan in the beagle dog.
Menargues, A; Nomen, M; Obach, R; Pruñonosa, J; Vallès, J, 1989
)
0.57
" Bioavailability values obtained after the oral administration of idazoxan ranged from 12."( Oral idazoxan bioavailability in rat. Relevance of intestinal and hepatic first-pass effect.
Menargues, A; Nomen, M; Obach, R; Pruñonosa, J; Vallès, J,
)
0.88
" Oral bioavailability in male rats at low oral doses of idazoxan (10 mg/kg) was about 1%, but increased with increasing dose to 23% at 100 mg/kg."( The pharmacokinetics and metabolism of idazoxan in the rat.
Havler, ME; Humphrey, MJ; Lewis, CJ; Lloyd-Jones, JG; McCleavy, MA; Muir, NC; Waltham, K, 1988
)
0.79
"Oral bioavailability (F) is a product of fraction absorbed (Fa), fraction escaping gut-wall elimination (Fg), and fraction escaping hepatic elimination (Fh)."( Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV, 2010
)
0.36
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Dose-response curves (DRCs) were obtained in the absence and cumulative presence of propranolol, corynanthine and idazoxan. Yohimbine caused about a 30 fold shift to the right in the dose-response curve. In response to infusions of the relatively selective alpha 2-adrenoceptor agonist alpha-methylnorepinephrine, the pressor dose- response curve shifted to the left.

ExcerptRelevanceReference
"01 mg/kg IP, twice daily for 14 days) produced a significant anxiolytic profile which was not a result of handling during the chronic dosing schedule, an effect was not measureable 24 h after treatment ended."( Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze.
Heaton, M; Marsden, CA; Upton, N; Wright, IK, 1992
)
0.5
" A higher dosage of clonidine (0."( Effects of alpha-noradrenergic substances on the optokinetic and vestibulo-ocular responses in the rabbit: a study with systemic and intrafloccular injections.
Collewijn, H; Pompeiano, O; Tan, HS; van Neerven, J, 1991
)
0.28
" Dose-response curves to noradrenaline were unaffected by prazosin (1 microM)."( Alpha 2-adrenoceptor antisecretory responses in the rat jejunum.
Dettmar, PW; Downing, OA; Roach, AG; Urquhart, CJ; Williams, RJ; Wilson, KA, 1990
)
0.28
" Pretreatment with the same dose of yohimbine or idazoxan shifted the rilmenidine dose-response curves for its hypotensive and bradycardic effects to the right."( Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit.
Belcourt, A; Bousquet, P; Bricca, G; Dontenwill, M; Feldman, J; Tibiriça, E, 1990
)
0.53
" The high dosage regimen (10 mg/kg per dose) of phentolamine or idazoxan that had been found to be hepatoprotective in earlier studies potentiated this hypothermia and more than doubled the net decrease in core body temperature experienced by the animals."( Antagonism of bromobenzene-induced hepatotoxicity by the alpha-adrenoreceptor blocking agents phentolamine and idazoxan: role of hypothermia.
Harbison, RD; James, RC; Kerger, BD; Roberts, SM, 1989
)
0.73
" Yohimbine caused about a 30 fold shift to the right in the dose-response curve whereas idazoxan almost completely abolished the mydriatic response to (+)-Amp."( Mechanism of dexamphetamine-induced mydriasis in the anaesthetized rat.
Hey, JA; Ito, T; Koss, MC, 1989
)
0.5
" Dose-response curves (DRCs) were obtained in the absence and cumulative presence of propranolol (PROP; beta-antagonist), corynanthine (CORY; alpha 1-antagonist) and idazoxan (IDX; alpha 2-antagonist) to estimate effective dosages (ED) required for 15 and 75% peak reductions in renal blood flow."( Unmasking sensitive alpha 2-adrenoceptor-mediated renal vasoconstriction in conscious rats.
Colindres, RE; Strandhoy, JW; Wolff, DW, 1989
)
0.47
" Idazoxan given at a dosage of 30 micrograms/kg also reversed xylazine-induced bradycardia."( Antagonistic effect of idazoxan on xylazine-induced central nervous system depression and bradycardia in calves.
Hsu, WH; Kersting, KW; Thompson, JR, 1989
)
1.5
" A U-shaped dose-response curve to compounds with mixed alpha 2- and alpha 1-antagonist properties may be constructed, which emphasizes the importance of the dose-dependent selectivity of these antagonists at alpha 2- and alpha 1-receptors."( Human vascular smooth muscle responses mediated by alpha 2 mechanisms in vivo and in vitro.
Calvete, J; Hayes, R; Martin, G; Sever, P; Thom, S, 1985
)
0.27
" Twenty-four hours after a single dose of desipramine (10 mg/kg, intraperitoneally) the inhibitory dose-response curves to either UK 14 304 or desipramine itself did not differ significantly from those seen in control animals, whereas both were displaced significantly to the right after 15 days pretreatment with desipramine."( Effects of desipramine on stimulation-induced contractions of the vas deferens of rats pretreated either chronically with desipramine or acutely with idazoxan.
Doxey, JC; Roach, AG; Samuel, J, 1985
)
0.47
" The loss of the righting reflex induced by clonidine in the chicken was prevented by (+/-) and (+) S9871, as shown by a shift of the dose-response curve to clonidine to the right by both agents; on the contrary, (-) S9871 potentiated the sedation induced by clonidine."( Antagonistic effects of S9871 or (imidazolinyl-2)-2-dihydro 2,3 benzofurane and its stereoisomers on some central and peripheral actions of alpha 2-agonists.
Joly, G; Mouillé, P; Schmitt, H, 1985
)
0.27
" Quantitative distribution patterns were route-dependent such that oral dosing resulted in lower radioactivity concentrations in all tissues apart from liver."( The pharmacokinetics and metabolism of idazoxan in the rat.
Havler, ME; Humphrey, MJ; Lewis, CJ; Lloyd-Jones, JG; McCleavy, MA; Muir, NC; Waltham, K, 1988
)
0.54
"5 ml/kg dosage of bromobenzene."( Antagonism of bromobenzene-induced hepatotoxicity by the alpha-adrenergic blocking agents, phentolamine and idazoxan.
Bucci, TJ; Gandy, J; Harbison, RD; James, RC; Kerger, BD; Roberts, SM, 1988
)
0.49
" The antagonism of both receptor types was reversible since washing of the tissues after incubation with DMPEA brought the agonist dose-response curve back to the control value."( Alpha-adrenoceptor occupancy by N,N-dimethyl-2-bromo-2-phenethylamine hydrobromide (DMPEA) in rat vas deferens.
Brasili, L; Cassinelli, A; Giardinà, D; Gulini, U; Melchiorre, C; Quaglia, W, 1988
)
0.27
" B-HT920 was found to produce a dose-response profile qualitatively similar to, but weaker than, clonidine: low doses impaired memory and began to lower blood pressure and produce sedation, while high doses improved memory."( The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects: evidence for alpha-2 receptor subtypes.
Arnsten, AF; Cai, JX; Goldman-Rakic, PS, 1988
)
0.27
" Cumulative dose-response curves were constructed for 8-OH-DPAT, ipsapirone and clonidine."( Evidence that the putative 5-HT1A receptor agonists, 8-OH-DPAT and ipsapirone, have a central hypotensive action that differs from that of clonidine in anaesthetised cats.
Fozard, JR; Ramage, AG, 1987
)
0.27
" caused significant falls in blood pressure and heart rate which were maximal 5 min after dosing (-29."( B-HT 958 lowers blood pressure and heart rate in the rat through stimulation of dopamine receptors.
Brown, MJ; Harland, D, 1986
)
0.27
" Dose-response curves were constructed to noradrenaline (alpha 1/alpha 2), methoxamine (alpha 1-selective) and B-HT 920 (alpha 2-selective)."( Characterization of post-junctional alpha-adrenoceptors in the rat isolated perfused femoral artery.
Dyke, AC; Widdop, RE, 1987
)
0.27
") produced about a 10 fold rightward shift of the dose-response curve for guanoxabenz."( alpha 2-Adrenoceptor agonists induced mydriasis in the rat by an action within the central nervous system.
Berridge, TL; Gadie, B; Roach, AG; Tulloch, IF, 1983
)
0.27
" There was a transient increase in blood pressure, and plasma noradrenaline, 10-20 min after dosing and an associated reduction in heart rate."( Evidence for postjunctional vascular alpha 2-adrenoceptors in peripheral vascular regulation in man.
Elliott, HL; Reid, JL, 1983
)
0.27
" Rauwolscine, RX 781094 and RS 21361 caused rightward parallel displacements of the log dose-response curve to the increase in diastolic pressure of methoxamine (alpha-1 agonist) and B-HT 920 (alpha-2 agonist) as well as to the B-HT 920-induced reduction in stimulation-evoked tachycardia."( A study of the selectivity and potency of rauwolscine, RX 781094 and RS 21361 as antagonists of alpha-1 and alpha-2 adrenoceptors.
Qian, JQ; Ruffolo, RR; Timmermans, PB; van Zwieten, PA, 1984
)
0.27
" In response to infusions of the relatively selective alpha 2-adrenoceptor agonist alpha-methylnorepinephrine, the pressor dose-response curve shifted to the right with idazoxan."( The alpha adrenoceptor antagonist properties of idazoxan in normal subjects.
Elliott, HL; Jones, CR; Lawrie, CB; Reid, JL; Vincent, J, 1984
)
0.72
" The pressor dose-response analysis for three agonists of varying selectivities for alpha 1 and alpha 2-adrenoceptors showed only modest changes with phenylephrine and noradrenaline with dose ratios less than 2, in contrast to the marked antagonism by RX781094 of the pressor response to the alpha 2 agonist, alphamethylnoradrenaline, dose ratio greater than 20."( Peripheral pre and postjunctional alpha 2-adrenoceptors in man: studies with RX781094, a selective alpha 2 antagonist.
Elliott, HL; Jones, CR; Reid, JL, 1983
)
0.27
" However, vasoconstriction due to clonidine post-ENDT even at maximal dosage (10(-3) M), was greatly attenuated in all four branching orders as in group II."( Attenuation of arteriolar alpha 2-adrenoceptor sensitivity during endotoxemia.
Baker, CH; Nessellroth, S; Ortiz-Tweed, M; Price, JM; Sutton, ET, 1994
)
0.29
"The dose-response curves for a number of alpha-adrenergic drugs were investigated to estimate a possible role of the alpha 2/alpha 1 selectivity of these drugs on the incidence of cortical high voltage spindles (HVS), reflecting level of vigilance."( Some unusual effects of alpha 2-adrenergic drugs on cortical high voltage spindles in rats.
Haapalinna, A; Riekkinen, P; Sirviö, J; Yavich, L, 1994
)
0.29
" In the first series of experiments the dose-response effects of dorsal and median raphe injection of 8-OH-DPAT in addition to PVN NE on feeding were examined."( Paraventricular nucleus injections of idazoxan block feeding induced by paraventricular nucleus norepinephrine but not intra-raphe 8-hydroxy-2-(di-n-propylamino)tetralin.
Coscina, DV; Currie, PJ, 1993
)
0.56
"5 to 37 fold) to the right of the dose-response curve for clonidine without significant change of maximum inhibitory effect, in a manner compatible with competitive antagonism (ED50B = 29."( Modulation by central postsynaptic alpha 2-adrenoceptors of the jaw-opening reflex induced by orofacial stimulation in rats.
Barturen, F; García-Sevilla, JA; García-Vallejo, P, 1994
)
0.29
" Castrated Strain 2 males, which show lordosis behavior without gonadal hormone administration, were injected with the same dosage of idazoxan (10 mg/kg) or with vehicle."( Idazoxan decreases estrogen-induced lordosis in female but not "hormone-independent" lordosis in male guinea pigs of an inbred strain.
Feder, HH; Goy, RW; McEwen, BS; Roy, M; Thornton, JE; Vincent, P, 1993
)
1.93
" The dose-response curve for the effect of clonidine on NE was shifted to the left in the latter group."( Presynaptic alterations associated with enhancement of evoked release and synthesis of norepinephrine in hippocampus of chronically cold-stressed rats.
Abercrombie, ED; Nisenbaum, LK, 1993
)
0.29
" The idazoxan dose-response curve for this suppression of fentanyl antinociception assessed with tail flick latency was the same as that for suppression of xylazine."( Antinociceptive actions of intrathecal xylazine: interactions with spinal cord opioid pathways.
Davies, A; Gent, JP; Goodchild, CS; Guo, Z, 1996
)
0.81
"We determined the relative potency of these drugs with respect to their effects on mean arterial pressure and heart rate by performing cumulative intravenous dose-response relationship studies in six conscious rabbits."( Relative importance of central imidazoline receptors for the antihypertensive effects of moxonidine and rilmenidine.
Chan, CK; Head, GA, 1996
)
0.29
" These results are different from those previously obtained in rats, which show bell-shaped dose-response curves in response to alpha 2 adrenoceptor blockers (small doses increased, while large doses decreased aggression)."( The effect of alpha 2 adrenoceptor blockers on aggressive behavior in mice: implications for the actions of adrenoceptor agents.
Haller, J; Kovács, JL; Makara, GB, 1996
)
0.29
" The antagonists could be divided in two classes: those that displayed surmountable inhibition (right-shift of the agonist dose-response curve), and those that displayed different degrees of insurmountable inhibition (depression of the maximum signal and a possible right-shift of the agonist dose-response curve)."( Different apparent modes of inhibition of alpha2A-adrenoceptor by alpha2-adrenoceptor antagonists.
Akerman, KE; Cockcroft, V; Huifang, G; Jansson, CC; Kukkonen, JP; Savola, JM; Wurster, S, 1997
)
0.3
" Dosage (mg/kg of body weight) of xylazine received, induction time, and recovery time after handling did not differ among sex-age classes."( Immobilization of mountain goats with xylazine and reversal with idazoxan.
Côté, SD; Festa-Bianchet, M; Haviernick, M, 1998
)
0.54
" It appears that low intravenous doses of fentanyl act mainly in the spinal cord and that increasing the dosage recruits descending inhibition."( The involvement of bulbospinal pathways in fentanyl-induced inhibition of spinal withdrawal reflexes in the decerebrated rabbit.
Clarke, RW; Houghton, AK; Ogilvie, J; Parry-Baggott, C, 1998
)
0.3
" In the presence of the opioid receptor antagonists, naloxone or naltrindole, the resulting nefopam dose-response relationships were shifted to the right."( The involvement of opioidergic and noradrenergic mechanisms in nefopam antinociception.
Gray, AM; Nevinson, MJ; Sewell, RD, 1999
)
0.3
"Clonidine, dobutamine, and dopexamine at high dosage suppress the gastric mucosal vasodilator response to acid back diffusion, which is an important defense mechanism."( Differential effects of clonidine, dopamine, dobutamine, and dopexamine on basal and acid-stimulated mucosal blood flow in the rat stomach.
Holzer, P; Painsipp, E, 2001
)
0.31
" In fetal, but not adult, MCA, UK-14304 induced a significant decrease in pD(2) for the phenylephrine dose-response relation."( Pre- and postjunctional alpha(2)-adrenergic receptors in fetal and adult ovine cerebral arteries.
Bishai, JM; Buchholz, JN; Gheorghe, CP; Longo, LD; Meulenaar, R; Nijland, R; Penninga, L; Zhang, L; Zhao, Y, 2002
)
0.31
"Initial dose-response curves to rilmenidine were determined in urethane anaesthetized rabbits."( Contribution of imidazoline receptors and alpha2-adrenoceptors in the rostral ventrolateral medulla to sympathetic baroreflex inhibition by systemic rilmenidine.
Burke, SL; Chan, CK; Head, GA, 2007
)
0.34
" The role of the α2C-AR in modulating two key depression-related behaviours in the Flinders Sensitive Line (FSL) rat was studied using a dose-response analysis following subcutaneous administration with the selective α2C-AR antagonist ORM-10921 (0."( The α2C-adrenoceptor antagonist, ORM-10921, exerts antidepressant-like effects in the Flinders Sensitive Line rat.
Harvey, BH; Sallinen, J; Shahid, M; Uys, MM, 2017
)
0.46
" Four weeks after inducing diabetes, tapentadol dose-response curves were obtained from animals pre-treated with RX821002 or naloxone (alpha2-adrenoceptors and opioid receptors antagonists, respectively)."( Opioid and noradrenergic contributions of tapentadol to the inhibition of locus coeruleus neurons in the streptozotocin rat model of polyneuropathic pain.
Berrocoso, E; Borges, GDS; Mico, JA; Torres-Sanchez, S, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
alpha-adrenergic antagonistAn agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
benzodioxineAny organic heterobicyclic compound containing ortho-fused benzene and dioxine rings.
imidazolinesDiazoline compounds having the nitrogen atoms at the 1- and 3-positions and a double bond at an unspecified position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (67)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Nrf2Homo sapiens (human)Potency23.10930.09208.222223.1093AID624149
thioredoxin reductaseRattus norvegicus (Norway rat)Potency7.51930.100020.879379.4328AID488773; AID588453
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency26.83253.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency25.15670.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency14.57500.004110.890331.5287AID493107
Fumarate hydrataseHomo sapiens (human)Potency35.48130.00308.794948.0869AID1347053
GLS proteinHomo sapiens (human)Potency5.62340.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency10.01710.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency0.47450.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency22.38720.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency28.11860.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency17.78280.011212.4002100.0000AID1030
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency11.88320.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency24.24930.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency21.13170.000417.946075.1148AID1346795
regulator of G-protein signaling 4Homo sapiens (human)Potency0.29930.531815.435837.6858AID504845
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency10.68220.000214.376460.0339AID720691
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency15.24560.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency1.89960.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency8.87340.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency33.48890.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency11.88320.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency30.00570.000229.305416,493.5996AID1259244; AID1259248; AID743078; AID743079
cytochrome P450 2D6Homo sapiens (human)Potency19.49710.00108.379861.1304AID1645840
polyproteinZika virusPotency35.48130.00308.794948.0869AID1347053
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency28.59860.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency74.97220.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency16.93010.023723.228263.5986AID743223
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency39.81070.035520.977089.1251AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency26.60320.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency14.14670.001628.015177.1139AID1224843; AID1224895
Histone H2A.xCricetulus griseus (Chinese hamster)Potency49.19400.039147.5451146.8240AID1224845; AID1224896
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency58.04790.01262.451825.0177AID485313
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency10.69100.134610.395030.1313AID1347049
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency7.49780.000323.4451159.6830AID743065; AID743067
histone deacetylase 9 isoform 3Homo sapiens (human)Potency18.83360.037617.082361.1927AID1259364
heat shock protein beta-1Homo sapiens (human)Potency14.14560.042027.378961.6448AID743210; AID743228
ras-related protein Rab-9AHomo sapiens (human)Potency58.04790.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency10.59430.00378.618923.2809AID2660; AID2666; AID2667; AID2668
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency12.83970.000627.21521,122.0200AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency15.84890.00798.23321,122.0200AID2551
gemininHomo sapiens (human)Potency16.08670.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency12.69880.005612.367736.1254AID624032; AID624044
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency33.49150.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency33.49150.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency33.49150.001551.739315,848.9004AID1259244
D(1A) dopamine receptorSus scrofa (pig)Potency6.56140.00378.108123.2809AID2667
Ataxin-2Homo sapiens (human)Potency39.81070.011912.222168.7989AID588378
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)134.00000.11007.190310.0000AID1443980; AID1473738
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)0.00830.00001.44217.3470AID36067
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.00670.00010.807410.0000AID1767747; AID306189; AID339888; AID650481
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.01950.00021.874210.0000AID35399
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki0.67870.00010.949010.0000AID36005; AID36010; AID37296
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)0.01950.00001.23808.1590AID35399
Alpha-2B adrenergic receptorHomo sapiens (human)Ki0.03760.00020.725710.0000AID1767747; AID306190; AID339892; AID650477
Alpha-2C adrenergic receptorHomo sapiens (human)IC50 (µMol)0.05370.00001.47257.8980AID36530
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.01480.00030.483410.0000AID1767747; AID306191; AID339896; AID650476
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Ki0.20680.00000.929610.0000AID35506; AID35624; AID36010
Amine oxidase [flavin-containing] AHomo sapiens (human)Ki0.01900.00192.379710.0000AID223240; AID223241
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Ki0.20680.00000.970810.0000AID35506; AID35624; AID36010
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Ki0.20680.00000.937510.0000AID35506; AID35624; AID36010
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.01950.00021.270410.0000AID35399
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Ki0.67870.00000.575110.0000AID36005; AID36010; AID37296
Amine oxidase [flavin-containing] BHomo sapiens (human)Ki0.01900.00061.777110.0000AID223240; AID223241
Alpha-1A adrenergic receptorHomo sapiens (human)IC50 (µMol)2.88400.00020.56145.4000AID36737
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.01950.00001.819410.0000AID35399
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki0.67870.00000.965010.0000AID36005; AID36010; AID37296
NischarinRattus norvegicus (Norway rat)Ki1.25890.00080.13881.2589AID1306517
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
NischarinHomo sapiens (human)Ki0.93700.00420.21923.8019AID223226; AID342861
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Kd0.74750.00020.52667.5858AID219618; AID35555; AID35726; AID35849; AID35872
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)Kd0.01390.00020.62779.3325AID35199; AID35476
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)Kd0.01390.00020.62779.3325AID35199; AID35476
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)Kd0.01390.00020.62779.3325AID35199; AID35476
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Kd0.74750.00020.89627.5858AID219618; AID35555; AID35726; AID35849; AID35872
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Kd0.78080.00020.51397.5858AID219618; AID35555; AID35726; AID35849; AID35872
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (263)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of heart rate involved in baroreceptor response to increased systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressureAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of heart rate by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of the force of heart contraction by epinephrine-norepinephrineAlpha-1A adrenergic receptorHomo sapiens (human)
apoptotic processAlpha-1A adrenergic receptorHomo sapiens (human)
smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
activation of phospholipase C activityAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1A adrenergic receptorHomo sapiens (human)
adult heart developmentAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of cell population proliferationAlpha-1A adrenergic receptorHomo sapiens (human)
response to xenobiotic stimulusAlpha-1A adrenergic receptorHomo sapiens (human)
response to hormoneAlpha-1A adrenergic receptorHomo sapiens (human)
negative regulation of autophagyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of action potentialAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of smooth muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
calcium ion transport into cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of cardiac muscle contractionAlpha-1A adrenergic receptorHomo sapiens (human)
cell growth involved in cardiac muscle cell developmentAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAlpha-1A adrenergic receptorHomo sapiens (human)
positive regulation of protein kinase C signalingAlpha-1A adrenergic receptorHomo sapiens (human)
pilomotor reflexAlpha-1A adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1A adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1A adrenergic receptorHomo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
apoptotic processNischarinHomo sapiens (human)
Rac protein signal transductionNischarinHomo sapiens (human)
actin cytoskeleton organizationNischarinHomo sapiens (human)
negative regulation of cell migrationNischarinHomo sapiens (human)
outer dynein arm assemblyNischarinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (81)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-1A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1A adrenergic receptorHomo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
integrin bindingNischarinHomo sapiens (human)
protein bindingNischarinHomo sapiens (human)
phosphatidylinositol bindingNischarinHomo sapiens (human)
identical protein bindingNischarinHomo sapiens (human)
dynein heavy chain bindingNischarinHomo sapiens (human)
alpha-tubulin bindingNischarinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (56)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
nucleusAlpha-1A adrenergic receptorHomo sapiens (human)
nucleoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1A adrenergic receptorHomo sapiens (human)
cytosolAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
caveolaAlpha-1A adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1A adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1A adrenergic receptorHomo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nucleoplasmNischarinHomo sapiens (human)
early endosomeNischarinHomo sapiens (human)
cytosolNischarinHomo sapiens (human)
plasma membraneNischarinHomo sapiens (human)
microtubule cytoskeletonNischarinHomo sapiens (human)
membraneNischarinHomo sapiens (human)
intracellular membrane-bounded organelleNischarinHomo sapiens (human)
intercellular bridgeNischarinHomo sapiens (human)
recycling endosomeNischarinHomo sapiens (human)
cytoplasmNischarinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (235)

Assay IDTitleYearJournalArticle
AID141670Inhibition of [3H]quinuclidinyl benzilate (QNB) binding from rat forebrain membranes in the presence of Zn; Not tested1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID35705In vitro postsynaptic antagonist potency at alpha-1 adrenergic receptor in rat anococcygeus. Taken as standard1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
alpha-adrenoreceptor reagents. 1. Synthesis of some 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists and potential antidepressants.
AID196034Inhibition of [3H]5-HT uptake into rat brain synaptosomes in vitro1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID1767777Cytotoxicity against human LN-229 cells at 100 uM by real time IncuCyte proliferation assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Benzofuranyl-2-imidazoles as imidazoline I
AID35360Antagonistic activity against alpha-2 adrenergic receptor in rat vas deferens1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Synthesis and structure-activity relationships of 2-sulfonamido-1,3,4,6,7,11b alpha-hexahydro-2H-benzo[a]quinolizines as alpha 2-adrenoceptor antagonists.
AID35902Binding activity against alpha-2 adrenergic receptor from calf cerebral cortex, using [3H]clonidine as the radioligand1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID37169Ability to displace [3H]prazosin from alpha-1 adrenergic receptor in rat brain homogenates in vitro1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID112006Antagonistic activity against Scopolamine induced behavioral deficits in mice; 5/61996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID35624Binding affinity to alpha-2 adrenergic receptor determined by measurement of [3H]yohimbine displacement from rat cortical membrane1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptors.
AID35849Alpha-1 adrenergic receptor pA2 value against norepinephrine in vitro experiment in rat anococcygeus.1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
alpha-adrenoreceptor reagents. 1. Synthesis of some 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists and potential antidepressants.
AID309557Displacement of [3H]2-BFI from I2-IBS in human frontal cortex membranes2007Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21
On the search of new I2-IBS aliphatic ligands: bis-guanidino carbonyl derivatives.
AID1767781Cytotoxicity against human DND41 cells at 100 uM by real time IncuCyte proliferation assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Benzofuranyl-2-imidazoles as imidazoline I
AID235857selectivity ratio (Alpha-1[Methoxiamine]/Alpha2[clonidine]1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID131878Effective dose required for inhibition of tetrabenazine-induced ptosis in mouse by peroral administration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID35626Binding affinity to alpha-2 adrenergic receptor of rat cerebral cortex assayed using [3H]yohimbine as radioligand1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Affinity of 2-(tetrahydroisoquinolin-2-ylmethyl)- and 2-(isoindolin-2-ylmethyl)imidazolines for alpha-adrenoceptors. Differential affinity of imidazolines for the [3H]idazoxan-labeled alpha 2-adrenoceptor vs the [3H]yohimbine-labeled site.
AID118349Antagonistic activity against Scopolamine induced behavioral deficits in mice at dose 5.0 mg/kg sc1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID1767755Permeability of compound by PAMPA-BBB assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Benzofuranyl-2-imidazoles as imidazoline I
AID36013Binding affinity determined to alpha-1 adrenergic receptor of rat cerebral cortex using [3H]prazosin as radioligand1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Affinity of 2-(tetrahydroisoquinolin-2-ylmethyl)- and 2-(isoindolin-2-ylmethyl)imidazolines for alpha-adrenoceptors. Differential affinity of imidazolines for the [3H]idazoxan-labeled alpha 2-adrenoceptor vs the [3H]yohimbine-labeled site.
AID650477Displacement of [3H]RX821002 from human alpha2B adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Favourable involvement of α2A-adrenoreceptor antagonism in the I₂-imidazoline binding sites-mediated morphine analgesia enhancement.
AID1767743Displacement of [3H]2-BFI from imidazoline I2 receptor in post-mortem human brain frontal cortex membrane assessed as occupancy at high affinity site measured after 30 mins by liquid scintillation counting spectrometry2021European journal of medicinal chemistry, Oct-15, Volume: 222Benzofuranyl-2-imidazoles as imidazoline I
AID79507In vitro reversal of inhibitory effect of UK - 14304 on the contractile response of guinea pig ileum to field stimulation.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptors.
AID751734Displacement of [3H]Idazoxan from central-type imidazole receptor 2 imidazoline binding site in Wistar rat cerebral cortex at 10 uM after 30 mins relative to control2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID35366In vitro antagonistic activity against alpha-2 adrenergic receptor in isolated electrically stimulated rat vas deferens (clonidine-induced decrease in twitch height)1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID186828The rate of glucose disappearance between 5 and 30 minutes after glucose administration1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 1. Synthesis and biological activities of N-benzyl-N'-(arylalkyl)-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines .
AID650481Displacement of [3H]RX821002 from human alpha2A adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Favourable involvement of α2A-adrenoreceptor antagonism in the I₂-imidazoline binding sites-mediated morphine analgesia enhancement.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID179414In vivo inhibition of clonidine induced mydriasis in the rat following i.v. administration.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptors.
AID180484Reversal of clonidine-induced mydriasis in rat, after intravenous administration1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.
AID650480Antagonist activity at human Alpha-2C adrenergic receptor expressed in CHO cells assessed as inhibition of clonidine-induced extracellular acidification after 30 mins by cytosensor microphysiometry2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Favourable involvement of α2A-adrenoreceptor antagonism in the I₂-imidazoline binding sites-mediated morphine analgesia enhancement.
AID175761Antagonistic potency towards alpha-2 adrenergic receptor was determined by observing twich response of rat vas deferens after i.v. administration1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Heteroaromatic analogues of the alpha 2-adrenoreceptor partial agonist clonidine.
AID118339Antagonistic activity against Scopolamine induced behavioral deficits in mice at dose 0.63 mg/kg sc1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID35864Antagonistic activity against postsynaptic Alpha-1 adrenergic receptor in isolated rat vas deferens using (-)-phenylephrine as agonist1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Berbanes: a new class of selective alpha 2-adrenoceptor antagonists.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID234973Selectivity as antilog of pKi [3H]yohimbine minus pKi [3H]-prazosin.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.
AID1767784Cytotoxicity against human Z138 cells at 100 uM by real time IncuCyte proliferation assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Benzofuranyl-2-imidazoles as imidazoline I
AID219799Tested for the alpha-2-adrenoceptor blocking activity by antagonism of clonidine-induced depression of the twitch responses of the field-stimulated prostatic portion of isolated rat vas deferens1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
Structure-activity relationships in 1,4-benzodioxan-related compounds. 4. Effect of aryl and alkyl substituents at position 3 on alpha-adrenoreceptor blocking activity.
AID179506The glycemia values 30 minutes after glucose administration to streptozotocin rats1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 1. Synthesis and biological activities of N-benzyl-N'-(arylalkyl)-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines .
AID91715Binding affinity for imidazoline receptor I-2 in rabbit kidney homogenate (relative to [3H]-Idazoxan radioligand)2000Journal of medicinal chemistry, Mar-23, Volume: 43, Issue:6
3D-QSAR CoMFA study on imidazolinergic I(2) ligands: a significant model through a combined exploration of structural diversity and methodology.
AID751669Displacement of [3H]Idazoxan from central-type imidazole receptor 2 imidazoline binding site in Wistar rat cerebral cortex after 30 mins2013Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6
Cinnamides as selective small-molecule inhibitors of a cellular model of breast cancer stem cells.
AID35340Alpha-2 adrenergic receptor pA2 value against clonidine in vitro experiment in rat vas deferens1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
alpha-adrenoreceptor reagents. 1. Synthesis of some 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists and potential antidepressants.
AID177373Effective dose of the compound required to inhibit electrically evoked contractions of rat vas deferens after i.v. administration1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Heteroaromatic analogues of the alpha 2-adrenoreceptor partial agonist clonidine.
AID35349Alpha-2 adrenergic receptor antagonist activity in a rat vas deferens assay. Values ranges from 8.38-8.641985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Alpha-adrenoreceptor reagents. 3. Synthesis of some 2-substituted 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists.
AID36281Antagonistic activity against postsynaptic alpha-1 adrenergic receptor in rabbit pulmonary artery using l-norepinephrine as agonist1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Berbanes: a new class of selective alpha 2-adrenoceptor antagonists.
AID35218Ratio of pA2 values at alpha-1 and alpha-2 adrenergic receptors.1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis and alpha 2-adrenoceptor antagonist activity of some disulfonamidobenzoquinolizines.
AID36277Relative potency was determined with respect to Yohimbine against alpha-1 adrenergic receptor1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Berbanes: a new class of selective alpha 2-adrenoceptor antagonists.
AID36005Binding affinity against alpha-1 adrenergic receptor in rat cerebral cortical membrane, determined using [3H]prazosin as the radioligand1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.
AID444052Hepatic clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID444056Fraction escaping gut-wall elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID186827Rate of glucose disappearance between 5 and 30 min after glucose administration with an intraperitoneal administration of 100 (umol/kg) to STZ rats1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 2. Syntheses and biological activities of 1,4-dialkyl-, 1,4-dibenzyl, and 1-benzyl-4-alkyl-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines an
AID297456Displacement of [3H]RX821002 from adrenergic alpha2 receptor in human brain frontal cortex2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Guanidine and 2-aminoimidazoline aromatic derivatives as alpha(2)-adrenoceptor antagonists, 1: toward new antidepressants with heteroatomic linkers.
AID444058Volume of distribution at steady state in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID141668Inhibition of [3H]quinuclidinyl benzilate (QNB) binding from rat forebrain membranes in the absence of Zn; Not tested1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID230520Ratio of reversal clonidine-induced mydriasis in rat, after oral administration to reversal of clonidine-induced mydriasis in rat, after intravenous administration1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.
AID36530Binding affinity at human Alpha-2C adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central alpha 2-antagonistic activity as potential antidepressants.
AID171612Inhibition of clonidine (0.04 mg/kg) induced anti diarrhoeal effects in rats following s.c. administration.2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central alpha 2-antagonistic activity as potential antidepressants.
AID339888Displacement of [3H]RS79948-197 from human recombinant adrenergic alpha2A receptor expressed in CHO cells2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Alpha2-adrenoreceptors profile modulation. 4. From antagonist to agonist behavior.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID177381In vivo antagonist dose producing two fold shift of cirazoline in pithed rats. (postjunctional); agonist1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Indoline analogues of idazoxan: potent alpha 2-antagonists and alpha 1-agonists.
AID196665Antagonist potency for alpha 2 adrenoceptor1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Heteroaromatic analogues of the alpha 2-adrenoreceptor partial agonist clonidine.
AID35334Alpha-2 adrenergic receptor antagonist activity compared to idazoxan1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Alpha-adrenoreceptor reagents. 3. Synthesis of some 2-substituted 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists.
AID118346Antagonistic activity against Scopolamine induced behavioral deficits in mice at dose 2.5 mg/kg sc1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID223476In vivo antagonism of guanabenz-induced hypothermia in mice after peroral administration at a dose of 10-40 mg/kg2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
New substituted 1-(2,3-dihydrobenzo[1, 4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with alpha(2)-adrenoceptor antagonist activity.
AID36010Binding affinity to alpha-1 adrenergic receptor determined by measurement of [3H]prazosin displacement from rat cortical membrane1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptors.
AID223241Binding affinity for imidazoline receptor I-21995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.
AID342863Selectivity ratio of pKi for human imidazoline receptor 1 to pKi for human alpha2 adrenoceptors2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
QSAR study of imidazoline antihypertensive drugs.
AID35199Antagonism of rat alpha-2 adrenergic receptor from rat vas deferens1989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis and alpha 2-adrenoceptor antagonist activity of some disulfonamidobenzoquinolizines.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID306191Displacement of [3H]MK912 from adrenergic Alpha-2C receptor in HepG2 cells2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Novel 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran derivatives as selective alpha(2C)-adrenergic receptor antagonists.
AID35726Alpha-1 adrenergic receptor antagonist activity in a rat anococcygeus. Values ranges from 6.14-6.571985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Alpha-adrenoreceptor reagents. 3. Synthesis of some 2-substituted 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists.
AID179415In vivo inhibition of clonidine induced mydriasis in the rat following p.o. administration.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptors.
AID339889Antagonist activity at human recombinant adrenergic alpha2A receptor expressed in CHO cells2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Alpha2-adrenoreceptors profile modulation. 4. From antagonist to agonist behavior.
AID118335Antagonistic activity against Scopolamine induced behavioral deficits in mice at dose 0.31 mg/kg sc1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID342861Displacement of [125I]PIC from human imidazoline receptor 1 in human platelets analyzed under norepinephrine mask of alpha 2AR2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
QSAR study of imidazoline antihypertensive drugs.
AID36491Antagonist potency towards alpha-2 adrenergic receptor in the mouse isolated electrically stimulated vas deferens with reference to idazoxan (prejunctional)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Effect of methoxy substitution on the adrenergic activity of three structurally related alpha 2-adrenoreceptor antagonists.
AID233642Ratio of presynaptic antagonist potency to postsynaptic antagonist potency1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
alpha-adrenoreceptor reagents. 1. Synthesis of some 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists and potential antidepressants.
AID35796Conc. that produced 50% reversal of inhibitory effects of clonidine was determined and compared with compound. Compound taken as standard1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
alpha-adrenoreceptor reagents. 1. Synthesis of some 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists and potential antidepressants.
AID342860Displacement of [125I]PIC from human alpha2 adrenoceptors expressed in CHO cells2008Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15
QSAR study of imidazoline antihypertensive drugs.
AID36859In vitro inhibition of specific binding of [3H]- prazosin to alpha-1 adrenergic receptor site in rat brain membranes.2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
New substituted 1-(2,3-dihydrobenzo[1, 4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with alpha(2)-adrenoceptor antagonist activity.
AID35872Presynaptic antagonistic activity against alpha-1 adrenergic receptor from rat, isolated, field-stimulated vas deferens, using methoxamine as the agonist1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID171602Inhibition of Xylazine (15 mg/kg i.v.) induced loss of righting reflex in rats following i.v. administration.2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central alpha 2-antagonistic activity as potential antidepressants.
AID32094Inhibitory activity against acetylcholinesterase in rat striatal preparation1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID233670Selectivity ratio of compound towards alpha-2 adrenoceptor over alpha1 adrenoceptor of calf cerebral cortex1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID1767783Cytotoxicity against human K562 cells at 100 uM by real time IncuCyte proliferation assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Benzofuranyl-2-imidazoles as imidazoline I
AID650476Displacement of [3H]RX821002 from human Alpha-2C adrenergic receptor expressed in CHO cells after 30 mins by scintillation counting2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Favourable involvement of α2A-adrenoreceptor antagonism in the I₂-imidazoline binding sites-mediated morphine analgesia enhancement.
AID37296Binding affinity against alpha-1 adrenergic receptor was determined by the displacement of [3H]prazosin from rat brain cortical membranes; value ranges from 221-4991987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines.
AID231408Antilog of [3H]idazoxan pKi minus [3H]-yohimbine pKi1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Affinity of 2-(tetrahydroisoquinolin-2-ylmethyl)- and 2-(isoindolin-2-ylmethyl)imidazolines for alpha-adrenoceptors. Differential affinity of imidazolines for the [3H]idazoxan-labeled alpha 2-adrenoceptor vs the [3H]yohimbine-labeled site.
AID169593Antagonist activity against guanoxabenz-induced mydriasis in rat when given intra cerebrovascularly1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Heteroaromatic analogues of the alpha 2-adrenoreceptor partial agonist clonidine.
AID36067Binding affinity at human Alpha-2A adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central alpha 2-antagonistic activity as potential antidepressants.
AID1767744Displacement of [3H]2-BFI from imidazoline I2 receptor in post-mortem human brain frontal cortex membrane one site model measured after 30 mins by liquid scintillation counting spectrometry2021European journal of medicinal chemistry, Oct-15, Volume: 222Benzofuranyl-2-imidazoles as imidazoline I
AID1767747Displacement of [3H]-RX821002 from adrenergic alpha 2 receptor in post-mortem human brain frontal cortex membrane measured after 30 mins by liquid scintillation counting spectrometry2021European journal of medicinal chemistry, Oct-15, Volume: 222Benzofuranyl-2-imidazoles as imidazoline I
AID306190Displacement of [3H]MK912 from adrenergic alpha-2B receptor expressed in COS7 cells2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Novel 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran derivatives as selective alpha(2C)-adrenergic receptor antagonists.
AID233447Selectivity ratio measured as the pKi (alpha-2) /pKi(alpha-1) receptor values.1991Journal of medicinal chemistry, Feb, Volume: 34, Issue:2
Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptors.
AID650475Antagonist activity at human alpha2A adrenergic receptor expressed in CHO cells assessed as inhibition of clonidine-induced extracellular acidification after 30 mins by cytosensor microphysiometry2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Favourable involvement of α2A-adrenoreceptor antagonism in the I₂-imidazoline binding sites-mediated morphine analgesia enhancement.
AID35555Antagonist activity against alpha-1 adrenergic receptor of rat anococcygeus muscle; value ranges from 5.9-6.51989Journal of medicinal chemistry, Jan, Volume: 32, Issue:1
Synthesis and alpha 2-adrenoceptor antagonist activity of some disulfonamidobenzoquinolizines.
AID444055Fraction absorbed in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID1306517Displacement of [125I]PIC from Imidazoline-1 receptor in rat PC12 cell membrane by gamma counting method2016Bioorganic & medicinal chemistry, 07-15, Volume: 24, Issue:14
A combined ligand- and structure-based approach for the identification of rilmenidine-derived compounds which synergize the antitumor effects of doxorubicin.
AID35963Binding activity against alpha-1 adrenergic receptor from calf cerebral cortex, using [3H]-prazosin as the radioligand1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID306189Displacement of [3H]MK-912 from adrenergic alpha2A receptor in HT29 cells2007Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6
Novel 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran derivatives as selective alpha(2C)-adrenergic receptor antagonists.
AID1767746Displacement of [3H]2-BFI from imidazoline I2 receptor low affinity site in post-mortem human brain frontal cortex membrane two site model measured after 30 mins by liquid scintillation counting spectrometry2021European journal of medicinal chemistry, Oct-15, Volume: 222Benzofuranyl-2-imidazoles as imidazoline I
AID35399Binding affinity at human Alpha-2B adrenergic receptor in CHO cells by [3H]rauwolscine (1 nM) displacement.2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central alpha 2-antagonistic activity as potential antidepressants.
AID444057Fraction escaping hepatic elimination in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1561265Displacement of [3H]2-BFI from I2IR in Swiss mouse brain cortex incubated for 45 mins by liquid scintillation spectrometry2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Bicyclic α-Iminophosphonates as High Affinity Imidazoline I
AID650486Binding affinity to I2 imidazoline binding site2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Favourable involvement of α2A-adrenoreceptor antagonism in the I₂-imidazoline binding sites-mediated morphine analgesia enhancement.
AID650474Antagonist activity at human alpha2B adrenergic receptor expressed in CHO cells assessed as inhibition of clonidine-induced extracellular acidification after 30 mins by cytosensor microphysiometry2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Favourable involvement of α2A-adrenoreceptor antagonism in the I₂-imidazoline binding sites-mediated morphine analgesia enhancement.
AID194892The incremental glycemia values after glucose administration (0.5 g/kg iv), to rats treated with streptozotocin (35 mg/kg iv)1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 1. Synthesis and biological activities of N-benzyl-N'-(arylalkyl)-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines .
AID297460Increase in noradrenergic extracellular noradrenaline level in locally administered Sprague-Dawley rat by microdialysis assay2007Journal of medicinal chemistry, Sep-06, Volume: 50, Issue:18
Guanidine and 2-aminoimidazoline aromatic derivatives as alpha(2)-adrenoceptor antagonists, 1: toward new antidepressants with heteroatomic linkers.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID131891Effective dose required to antagonise clonidine-induced antinociception(ACA) in mouse by peroral administration;Values ranges from: 0.5-3.81987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID235856selectivity ratio (Alpha-1[3H]-prazosin/Alpha2[3H]-clonidine)1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID174903Incremental glycemia values over baseline integrated over 30 min after glucose administration (iv) at a concentration 0.5 g/kg1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 2. Syntheses and biological activities of 1,4-dialkyl-, 1,4-dibenzyl, and 1-benzyl-4-alkyl-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines an
AID233671Selectivity ratio for alpha-2 adrenoceptor over alpha1 adrenoceptor of rat vas deferens1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID177376In vivo ED40 is the raising diastolic blood pressure by 40 mm Hg in pithed rats. (postjunctional)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Indoline analogues of idazoxan: potent alpha 2-antagonists and alpha 1-agonists.
AID35479Alpha-2 adrenergic receptor antagonistic activity in rat vas deferens vs clonidin1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines.
AID36648Antagonistic activity against central alpha-2 adrenergic receptor, in anesthetized rats (reversal of clonidine-induced mydriasis)1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID218806Ability to displace [3H]clonidine from alpha-2 adrenergic receptor in rat brain homogenates in vitro1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID339896Displacement of [3H]RS79948-197 from human recombinant adrenergic Alpha-2C receptor expressed in CHO cells2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Alpha2-adrenoreceptors profile modulation. 4. From antagonist to agonist behavior.
AID229627Selectivity ratio represented as antilog (alpha-2 pA2 - alpha-1 pA2)1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Synthesis and structure-activity relationships of 2-sulfonamido-1,3,4,6,7,11b alpha-hexahydro-2H-benzo[a]quinolizines as alpha 2-adrenoceptor antagonists.
AID35506Binding affinity against alpha-2 adrenergic receptor in rat cerebral cortical membrane, determined using [3H]- yohimbine as the radioligand.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.
AID444053Renal clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID184366Maximum percent inhibition electrically evoked contractions of rat vas deferens by the compound was determined as test for its agonistic activity1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Heteroaromatic analogues of the alpha 2-adrenoreceptor partial agonist clonidine.
AID404333Increase in extracellular noradrenaline levels in Sprague-Dawley rat brain prefrontal cortex at 1 to 100 uM, ip locally administered by microdialysis by relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Guanidine and 2-aminoimidazoline aromatic derivatives as alpha2-adrenoceptor antagonists. 2. Exploring alkyl linkers for new antidepressants.
AID1767780Cytotoxicity against human NCI-H460 cells at 100 uM by real time IncuCyte proliferation assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Benzofuranyl-2-imidazoles as imidazoline I
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID118342Antagonistic activity against Scopolamine induced behavioral deficits in mice at dose 1.25 mg/kg sc1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID223464In vivo antagonism of guanabenz-induced hypothermia in mice after intraperitoneal administration at a dose of 0.63-10 mg/kg2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
New substituted 1-(2,3-dihydrobenzo[1, 4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with alpha(2)-adrenoceptor antagonist activity.
AID177383In vivo antagonist dose producing two fold shift of cirazoline in pithed rats. (prejunctional)1988Journal of medicinal chemistry, May, Volume: 31, Issue:5
Indoline analogues of idazoxan: potent alpha 2-antagonists and alpha 1-agonists.
AID223226Binding affinity for imidazoline receptor I-11995Journal of medicinal chemistry, Sep-15, Volume: 38, Issue:19
Alpha- and beta-adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications.
AID36918In vitro inhibition of binding of [3H]-RX-821002 to alpha-2 adrenergic receptor site in rat brain membranes.2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
New substituted 1-(2,3-dihydrobenzo[1, 4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with alpha(2)-adrenoceptor antagonist activity.
AID35625Binding affinity to the alpha-2 adrenergic receptor of rat cerebral cortex assayed using [3H]idazoxan as radioligand1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Affinity of 2-(tetrahydroisoquinolin-2-ylmethyl)- and 2-(isoindolin-2-ylmethyl)imidazolines for alpha-adrenoceptors. Differential affinity of imidazolines for the [3H]idazoxan-labeled alpha 2-adrenoceptor vs the [3H]yohimbine-labeled site.
AID218809In vitro antagonistic activity against alpha-2 adrenergic receptor in isolated electrically stimulated rat vas deferens (clonidine-induced decrease in twitch height)1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID35858Antagonist potency towards alpha-1 adrenergic receptor in the rat electrically stimulated vas deferens with reference to phenylephrine1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Effect of methoxy substitution on the adrenergic activity of three structurally related alpha 2-adrenoreceptor antagonists.
AID339897Antagonist activity at human recombinant adrenergic Alpha-2C receptor expressed in CHO cells2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Alpha2-adrenoreceptors profile modulation. 4. From antagonist to agonist behavior.
AID179376Percent of variation of glycemia value 30 mins after glucose administration by intraperitoneal dose of 100 uM/Kg to STZ rats compared to untreated rats1999Journal of medicinal chemistry, May-06, Volume: 42, Issue:9
Design and synthesis of imidazoline derivatives active on glucose homeostasis in a rat model of type II diabetes. 2. Syntheses and biological activities of 1,4-dialkyl-, 1,4-dibenzyl, and 1-benzyl-4-alkyl-2-(4',5'-dihydro-1'H-imidazol-2'-yl)piperazines an
AID196038Inhibitory activity against norepinephrine (NE) uptake in rat whole brain synaptosome preparation1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID180483Reversal clonidine-induced mydriasis in rat, after oral administration1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.
AID219618Ex vivo alpha-1-adrenoceptor blocking activity by antagonism of (-)-norepinephrine -induced contractions of the epididymal portion of isolated rat vas deferens.1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
Structure-activity relationships in 1,4-benzodioxan-related compounds. 4. Effect of aryl and alkyl substituents at position 3 on alpha-adrenoreceptor blocking activity.
AID1767745Displacement of [3H]2-BFI from imidazoline I2 receptor high affinity site in post-mortem human brain frontal cortex membrane two site model measured after 30 mins by liquid scintillation counting spectrometry2021European journal of medicinal chemistry, Oct-15, Volume: 222Benzofuranyl-2-imidazoles as imidazoline I
AID232213Selectivity as ratio of pA2 value against alpha-2 receptor to that of alpha-1 receptor.1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Alpha-adrenoreceptor reagents. 3. Synthesis of some 2-substituted 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists.
AID650484Potentiation of morphine-induced analgesic activity in CD1 mouse assessed as latency in radiant heat-induced tail flick at 2 mg/kg, ip administered 15 mins prior to morphine measured up to 120 mins2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Favourable involvement of α2A-adrenoreceptor antagonism in the I₂-imidazoline binding sites-mediated morphine analgesia enhancement.
AID444051Total clearance in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID35867In vitro antagonistic activity against alpha-1 adrenergic receptor in isolated electrically stimulated rat vas deferens (methoxamine-induced decrease in twitch height)1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID1767779Cytotoxicity against human HCT-116 cells at 100 uM by real time IncuCyte proliferation assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Benzofuranyl-2-imidazoles as imidazoline I
AID35577Alpha-1 adrenergic receptor binding activity relative to idazoxan.1985Journal of medicinal chemistry, Aug, Volume: 28, Issue:8
Alpha-adrenoreceptor reagents. 3. Synthesis of some 2-substituted 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists.
AID35873The compound was evaluated for the alpha-1 adrenergic receptor antagonistic activity in rat vas deferens vs methoxamine alpha-1 adrenoceptor antagonism1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines.
AID80588Ability to reverse inhibitory effects of UK-14304 on the contraction of guinea pig ileum as a measure of alpha-2 adrenergic receptor antagonism.1989Journal of medicinal chemistry, Sep, Volume: 32, Issue:9
(8a alpha,12a alpha,13a alpha)-5,8,8a,9,10,11,12,12a,13,13a-decahydro- 3-methoxy-12-(methylsulfonyl)-6H-isoquino[2,1-g][1,6]naphthyridi ne, a potent and highly selective alpha 2-adrenoceptor antagonist.
AID196033Inhibition of [3H]norepinephrine uptake into rat brain synaptosomes in vitro;Values ranges from: 8.6-211987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID35793In vitro presynaptic agonist potency at alpha-2 adrenergic receptor in rat or mouse vas deferens relative to clonidine; IA means inactive1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
alpha-adrenoreceptor reagents. 1. Synthesis of some 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists and potential antidepressants.
AID36737Binding affinity at human Alpha-1A adrenergic receptor in CHO cells uby [3H]prazosin (0.25 nM) displacement.2000Bioorganic & medicinal chemistry letters, Jan-03, Volume: 10, Issue:1
New 2-substituted 1,2,3,4-tetrahydrobenzofuro[3,2-c]pyridine having highly active and potent central alpha 2-antagonistic activity as potential antidepressants.
AID35357Antagonist potency towards alpha-2 adrenergic receptor in the rat electrically stimulated vas deferens with reference to P-aminoclonidine1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Effect of methoxy substitution on the adrenergic activity of three structurally related alpha 2-adrenoreceptor antagonists.
AID225960Minimum effective dose required for inhibition of serotonin uptake was determined by PCA method in rat by peroral administration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID339892Displacement of [3H]RS79948-197 from human recombinant adrenergic alpha2B receptor expressed in CHO cells2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Alpha2-adrenoreceptors profile modulation. 4. From antagonist to agonist behavior.
AID234376Selectivity ratio is the antilog of the difference between pA2 values at alpha1- and alpha2- adrenoceptors1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
Structure-activity relationships in 1,4-benzodioxan-related compounds. 4. Effect of aryl and alkyl substituents at position 3 on alpha-adrenoreceptor blocking activity.
AID36058Antagonistic activity against longitudinal muscle strip of the guinea pig ileum using xylazine as agonist1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Berbanes: a new class of selective alpha 2-adrenoceptor antagonists.
AID35580In vitro postsynaptic agonist potency at alpha-1 adrenergic receptor in rat anococcygeus muscle relative to phenylephrine; IA means inactive.1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
alpha-adrenoreceptor reagents. 1. Synthesis of some 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists and potential antidepressants.
AID1561264Displacement of [3H]2-BFI from I2IR in Sprague-Dawley rat brain cortex incubated for 45 mins by liquid scintillation spectrometry2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Bicyclic α-Iminophosphonates as High Affinity Imidazoline I
AID35476Presynaptic antagonistic activity against alpha-2 adrenergic receptor from rat, isolated, field-stimulated vas deferens, using clonidine as the agonist1983Journal of medicinal chemistry, Dec, Volume: 26, Issue:12
Pyridinylpiperazines, a new class of selective alpha 2-adrenoceptor antagonists.
AID1767778Cytotoxicity against human CAPAN-1 cells at 100 uM by real time IncuCyte proliferation assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Benzofuranyl-2-imidazoles as imidazoline I
AID35565Antagonist potency towards alpha-1 adrenergic receptor in the rat isolated electrically stimulated vas deferens with reference to pA2 idazoxan (postjunctional)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Effect of methoxy substitution on the adrenergic activity of three structurally related alpha 2-adrenoreceptor antagonists.
AID64430In vitro inhibition of specific binding of [3H]-YM 09151-2 to Dopamine receptor D2 site in rat striatal tissue.2000Journal of medicinal chemistry, Oct-05, Volume: 43, Issue:20
New substituted 1-(2,3-dihydrobenzo[1, 4]dioxin-2-ylmethyl)piperidin-4-yl derivatives with alpha(2)-adrenoceptor antagonist activity.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID36057Antagonistic activity against adrenergic alpha-2 receptor in longitudinal muscle strip of the guinea pig ileum using l-norepinephrine as agonist1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Berbanes: a new class of selective alpha 2-adrenoceptor antagonists.
AID404330Displacement of [3H]RX821002 from alpha2 adrenergic receptor in human brain prefrontal cortex tissue by liquid scintillation spectrometry2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Guanidine and 2-aminoimidazoline aromatic derivatives as alpha2-adrenoceptor antagonists. 2. Exploring alkyl linkers for new antidepressants.
AID233641Ratio of pA2 value against alpha2 to alpha-1 adrenoceptor1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
alpha-adrenoreceptor reagents. 1. Synthesis of some 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists and potential antidepressants.
AID150844Displacement of [3H]DAMGO (2 nM ) from opioid receptor mu 1 in human brain; nd indicates not determined2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: a new series of hybrid molecules with significant binding affinity for mu-opioid receptors and I2-imidazoline binding sites.
AID1561261Displacement of [3H]2-BFI from I2IR in human brain frontal cortex assessed as binding affinity at high affinity site incubated for 45 mins by liquid scintillation spectrometry2020Journal of medicinal chemistry, 04-09, Volume: 63, Issue:7
Bicyclic α-Iminophosphonates as High Affinity Imidazoline I
AID36946Ability to displace [3H]-clonidine from alpha-1 adrenergic receptor in rat brain homogenates in vitro1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID35563Agonist potency towards alpha-1 adrenergic receptor in the rat isolated electrically stimulated vas deferens with reference to phenylephrine (postjunctional)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Effect of methoxy substitution on the adrenergic activity of three structurally related alpha 2-adrenoreceptor antagonists.
AID35771Compound was evaluated for Alpha-2 adrenergic receptor antagonist activity;no data2003Journal of medicinal chemistry, May-08, Volume: 46, Issue:10
Synthesis and biological evaluation of new 2-(4,5-dihydro-1H-imidazol-2-yl)-3,4-dihydro-2H-1,4-benzoxazine derivatives.
AID1767782Cytotoxicity against human HL-60 cells at 100 uM by real time IncuCyte proliferation assay2021European journal of medicinal chemistry, Oct-15, Volume: 222Benzofuranyl-2-imidazoles as imidazoline I
AID364880Displacement of [3H]RX821002 from alpha2 adrenoceptor in human prefrontal cortex neural membrane2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
Novel synthesis and pharmacological evaluation as alpha2-adrenoceptor ligands of O-phenylisouronium salts.
AID235334Selectivity ratio (Alpha-1: Alpha-2)1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Berbanes: a new class of selective alpha 2-adrenoceptor antagonists.
AID132448Antagonistic activity against clonidine-induced antinociception in mouse after po administration1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines.
AID233431Selectivity ratio for alpha 2 adrenergic receptor subpopulation, [3H]yohimbine pKi minus [3H]-prazosin pKi1990Journal of medicinal chemistry, Feb, Volume: 33, Issue:2
Affinity of 2-(tetrahydroisoquinolin-2-ylmethyl)- and 2-(isoindolin-2-ylmethyl)imidazolines for alpha-adrenoceptors. Differential affinity of imidazolines for the [3H]idazoxan-labeled alpha 2-adrenoceptor vs the [3H]yohimbine-labeled site.
AID114184Effective dose against, administration in mice; Not tested1996Journal of medicinal chemistry, Jan-19, Volume: 39, Issue:2
Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease.
AID196026Inhibition of [3H]dopamine uptake into rat brain synaptosomes in vitro1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and antidepressant properties of novel 2-substituted 4,5-dihydro-1H-imidazole derivatives.
AID36489Agonist potency towards alpha-2 adrenergic receptor in the mouse isolated electrically stimulated vas deferens with reference to clonidine (prejunctional)1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Effect of methoxy substitution on the adrenergic activity of three structurally related alpha 2-adrenoreceptor antagonists.
AID35861Antagonistic activity against alpha-1 adrenergic receptor in isolated rat anococcygeus muscle1988Journal of medicinal chemistry, Jul, Volume: 31, Issue:7
Synthesis and structure-activity relationships of 2-sulfonamido-1,3,4,6,7,11b alpha-hexahydro-2H-benzo[a]quinolizines as alpha 2-adrenoceptor antagonists.
AID444054Oral bioavailability in human2010Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
AID35361Antagonistic activity against presynaptic alpha-2 adrenergic receptor in isolated rat vas deferens using xylazine as agonist1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Berbanes: a new class of selective alpha 2-adrenoceptor antagonists.
AID339893Antagonist activity at human recombinant adrenergic alpha2B receptor expressed in CHO cells2008Journal of medicinal chemistry, Jul-24, Volume: 51, Issue:14
Alpha2-adrenoreceptors profile modulation. 4. From antagonist to agonist behavior.
AID223240Displacement of [3H]2-BFI (1 nM) from imidazoline receptor I-2 in human brain2004Bioorganic & medicinal chemistry letters, Jan-19, Volume: 14, Issue:2
Fentanyl derivatives bearing aliphatic alkaneguanidinium moieties: a new series of hybrid molecules with significant binding affinity for mu-opioid receptors and I2-imidazoline binding sites.
AID368169Displacement of [3H]RX821002 from alpha2 adrenoceptor in human prefrontal cortex neural membrane after 30 mins by liquid scintillation spectrometry2009Journal of medicinal chemistry, Feb-12, Volume: 52, Issue:3
Guanidine and 2-aminoimidazoline aromatic derivatives as alpha2-adrenoceptor ligands: searching for structure-activity relationships.
AID37078Binding affinity against alpha-2 adrenergic receptor was determined by the displacement of [3H]clonidine from rat brain cortical membranes1987Journal of medicinal chemistry, Sep, Volume: 30, Issue:9
Alpha 2-adrenergic agonists/antagonists: the synthesis and structure-activity relationships of a series of indolin-2-yl and tetrahydroquinolin-2-yl imidazolines.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,465)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990322 (21.98)18.7374
1990's738 (50.38)18.2507
2000's262 (17.88)29.6817
2010's131 (8.94)24.3611
2020's12 (0.82)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.04 (24.57)
Research Supply Index7.34 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index50.74 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials40 (2.67%)5.53%
Reviews17 (1.13%)6.00%
Case Studies1 (0.07%)4.05%
Observational0 (0.00%)0.25%
Other1,441 (96.13%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
I2PETPG - Quantification and Localisation of Imidazoline2 Binding Sites in a Group of Participants Diagnosed With Alzheimer's Disease Using 11C-BU99008: a Positron Emission Tomography Study [NCT02874820]Early Phase 12 participants (Actual)Interventional2016-07-31Terminated(stopped due to Patient recruitment issues.)
A Phase 1 Safety, Tolerability and Pharmacokinetic Study of R-Idazoxan HCl Extended-Release (TR-01-XRR), S-Idazoxan HCl Extended-Release (TR-01-XRS) and Racemic Idazoxan HCl Extended-Release (TR-01-XR) in Healthy Participants [NCT05727189]Phase 1150 participants (Anticipated)Interventional2023-02-14Recruiting
[NCT00294944]Phase 30 participants InterventionalWithdrawn
I2PETHV - Quantification and Localisation of Imidazoline2 Binding Sites in Healthy Volunteers Using [11C]BU99008 a Positron Emission Tomography Study [NCT02323217]Early Phase 120 participants (Actual)Interventional2015-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT02323217 (3) [back to overview]Determination of the Regional Density and Distribution of I2BS in Healthy Human Brain (1TCM Model)
NCT02323217 (3) [back to overview]Determination of the Regional Density and Distribution of I2BS in Healthy Human Brain (2TCM Model)
NCT02323217 (3) [back to overview]Determination of the Regional Density and Distribution of I2BS in Healthy Human Brain (MA Model)

Determination of the Regional Density and Distribution of I2BS in Healthy Human Brain (1TCM Model)

"The determination of the regional density and distribution of the I2BS in human brain of healthy volunteers. The output parameter used to determine this will be derived from the most appropriate PET pharmacokinetic model for this ligand in human e.g. Total Volume of Distribution (VT) or Binding Potential (BP).~Regional time-activity data were generated from arterial plasma input functions corrected for metabolites using the most appropriate model to derive the outcome measure VT (regional distribution volume). All image processing and kinetic analyses were performed in MIAKAT. The Akaike model selection criteria were used to determine the most appropriate model to describe these data.~The calculated criteria for the three main models are: one-tissue (1TCM) and two-tissue (2TCM) compartmental models, and multilinear analysis model (MA)." (NCT02323217)
Timeframe: 1 week

InterventionmL/cm^3 (Mean)
Whole BrainCerebellumBrain stemOccipital lobeInsulaFrontal lobeCingulateParietal lobeAmygdalaHippocampusStriatumThalamus
Healthy Volunteers44.539.362.738.663.341.658.339.289.868.4102.775.3

[back to top]

Determination of the Regional Density and Distribution of I2BS in Healthy Human Brain (2TCM Model)

"The determination of the regional density and distribution of the I2BS in human brain of healthy volunteers. The output parameter used to determine this will be derived from the most appropriate PET pharmacokinetic model for this ligand in human e.g. Total Volume of Distribution (VT) or Binding Potential (BP).~Regional time-activity data were generated from arterial plasma input functions corrected for metabolites using the most appropriate model to derive the outcome measure VT (regional distribution volume). All image processing and kinetic analyses were performed in MIAKAT. The Akaike model selection criteria were used to determine the most appropriate model to describe these data.~The calculated criteria for the three main models are: one-tissue (1TCM) and two-tissue (2TCM) compartmental models, and multilinear analysis model (MA)." (NCT02323217)
Timeframe: 1 week

InterventionmL/cm^3 (Mean)
Whole BrainCerebellumBrain stemOccipital lobeInsulaFrontal lobeCingulateParietal lobeAmygdalaHippocampusStriatumThalamus
Healthy Volunteers48.841.966.442.767.745.762.243.694.677.7105.780.0

[back to top]

Determination of the Regional Density and Distribution of I2BS in Healthy Human Brain (MA Model)

"The determination of the regional density and distribution of the I2BS in human brain of healthy volunteers. The output parameter used to determine this will be derived from the most appropriate PET pharmacokinetic model for this ligand in human e.g. Total Volume of Distribution (VT) or Binding Potential (BP).~Regional time-activity data were generated from arterial plasma input functions corrected for metabolites using the most appropriate model to derive the outcome measure VT (regional distribution volume). All image processing and kinetic analyses were performed in MIAKAT. The Akaike model selection criteria were used to determine the most appropriate model to describe these data.~The calculated criteria for the three main models are: one-tissue (1TCM) and two-tissue (2TCM) compartmental models, and multilinear analysis model (MA)." (NCT02323217)
Timeframe: 1 week

InterventionmL/cm^3 (Mean)
Whole BrainCerebellumBrain stemOccipital lobeInsulaFrontal lobeCingulateParietal lobeAmygdalaHippocampusStriatumThalamus
Healthy Volunteers44.839.663.238.863.942.058.839.591.169.1104.276.0

[back to top]